The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide

Cet article décrit les sources et les méthodes utilisées par GLOBOCAN 2022 (185 pays ou territoires couverts) pour estimer l'incidence de 36 localisations de cancer et la mortalité associée puis présente de manière synthétique ces résultats

Résumé en anglais

The data sources and methods used to develop global cancer incidence and mortality statistics—the GLOBOCAN estimates—for the year 2022 are documented in this article, alongside a brief overview of the global cancer burden. The estimates, made available in 185 countries or territories worldwide for 36 cancer sites by sex and age, are based on the best available local data sources, namely population-based cancer registries (for incidence) and national vital statistics (for mortality). In males, lung cancer was the most commonly diagnosed cancer worldwide in 2022 (1.57 million new cases [95% UI: 1.56–1.58]), followed by prostate cancer (1.47 million [1.46–1.48]). With 2.30 million (2.28–2.30) new cases estimated in 2022, breast cancer was the most diagnosed cancer in females, followed by lung cancer (0.91 million [0.90–0.91 million]) and cervical cancer (0.66 million [0.66–0.67]). The most common causes of cancer death in males and females were lung cancer (1.23 million [1.22–1.24]) and breast cancer (0.67 million [0.66–0.67]), respectively.